Florian Eisele

411 total citations
12 papers, 259 citations indexed

About

Florian Eisele is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Florian Eisele has authored 12 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 5 papers in Pathology and Forensic Medicine and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Florian Eisele's work include CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Florian Eisele is often cited by papers focused on CAR-T cell therapy research (6 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Lymphoma Diagnosis and Treatment (4 papers). Florian Eisele collaborates with scholars based in Germany, Denmark and United States. Florian Eisele's co-authors include Johannes Duell, Leo Rasche, Max S. Topp, Hermann Einsele, Andreas Rosenwald, Tobias Mueller, Elena Hartmann, Tanja Bedke, Marcus Dittrich and Thomas Dandekar and has published in prestigious journals such as Blood, Leukemia and Journal of Immunotherapy.

In The Last Decade

Florian Eisele

10 papers receiving 255 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Florian Eisele Germany 6 207 89 82 63 63 12 259
Evelyn Degenhard Germany 4 326 1.6× 142 1.6× 133 1.6× 90 1.4× 75 1.2× 4 412
S. Schuster United States 6 199 1.0× 123 1.4× 32 0.4× 124 2.0× 79 1.3× 11 330
Marion Subklewe Germany 6 180 0.9× 95 1.1× 24 0.3× 19 0.3× 114 1.8× 36 276
Jan Bögeholz Switzerland 4 117 0.6× 83 0.9× 37 0.5× 14 0.2× 95 1.5× 5 204
Veit Buecklein Germany 7 160 0.8× 62 0.7× 27 0.3× 22 0.3× 69 1.1× 32 230
Kirstie L.S. Cleary United Kingdom 7 84 0.4× 120 1.3× 93 1.1× 36 0.6× 30 0.5× 11 213
Patrycja Wawrzyniecka United Kingdom 6 239 1.2× 110 1.2× 15 0.2× 87 1.4× 19 0.3× 16 300
Horst Hummel Germany 4 266 1.3× 164 1.8× 121 1.5× 133 2.1× 16 0.3× 4 326
Daniel Egan United States 8 123 0.6× 49 0.6× 16 0.2× 17 0.3× 127 2.0× 22 212
Anna Truppel-Hartmann United States 10 223 1.1× 65 0.7× 46 0.6× 51 0.8× 130 2.1× 22 289

Countries citing papers authored by Florian Eisele

Since Specialization
Citations

This map shows the geographic impact of Florian Eisele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Florian Eisele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Florian Eisele more than expected).

Fields of papers citing papers by Florian Eisele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Florian Eisele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Florian Eisele. The network helps show where Florian Eisele may publish in the future.

Co-authorship network of co-authors of Florian Eisele

This figure shows the co-authorship network connecting the top 25 collaborators of Florian Eisele. A scholar is included among the top collaborators of Florian Eisele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Florian Eisele. Florian Eisele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Duell, Johannes, Diana Alvarez Arias, Hilka Rauert‐Wunderlich, et al.. (2025). Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings. Transplantation and Cellular Therapy. 31(2). S394–S394. 1 indexed citations
2.
3.
Fleischmann, Maximilian, Madlen Jentzsch, Annamaria Brioli, et al.. (2024). Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Annals of Hematology. 104(1). 285–294. 2 indexed citations
4.
Duell, Johannes, Diana Alvarez Arias, Hilka Rauert‐Wunderlich, et al.. (2024). Maintenance of CD19 Expression after Tafasitamab Treatment in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) from Clinical Trial and Real-World Settings. Blood. 144(Supplement 1). 2991–2991.
5.
Duell, Johannes, Alexander M. Leipold, Silke Appenzeller, et al.. (2023). Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell–redirecting therapy. Blood. 143(8). 685–696. 25 indexed citations
6.
Eisele, Florian, Xiang Zhou, M Steinhardt, et al.. (2023). Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma. Annals of Hematology. 103(4). 1327–1332. 5 indexed citations
7.
Haertle, Larissa, Cornelia Vogt, Xiang Zhou, et al.. (2023). Functional Characterization of GPRC5D alteration and Its Impact on Talquetamab Resistance in Relapsed/ Refractory Multiple Myeloma. Blood. 142(Supplement 1). 3323–3323. 2 indexed citations
8.
Eisele, Florian, Johannes Duell, Johannes M. Waldschmidt, et al.. (2023). The Impact of Treatment-Free Intervals on T-Cell Exhaustion and Clonotypic Diversity in Myeloma Patients Treated with BCMA Bispecific Antibodies. Blood. 142(Supplement 1). 1938–1938. 7 indexed citations
9.
Rasche, Leo, Marietta Truger, Florian Eisele, et al.. (2023). OA-24 Sequential and persistent loss of BCMA and GPRC5D after bispecific antibodies in multiple myeloma revealed by whole genome sequencing. Clinical Lymphoma Myeloma & Leukemia. 23. S15–S15. 1 indexed citations
10.
Duell, Johannes, Margarete M. Karg, Uwe Reusch, et al.. (2019). Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. Journal of Immunotherapy. 42(5). 180–188. 15 indexed citations
11.
Duell, Johannes, Gerhard Zugmaier, Florian Eisele, et al.. (2019). PB1780 TREATMENT OF R/R BURKITT LYMPHOMA WITH BLINATUMOMAB IS FEASIBLE AND INDUCED A LONG LASTING COMPLETE REMISSION. HemaSphere. 3(S1). 816–817. 6 indexed citations
12.
Duell, Johannes, Marcus Dittrich, Tanja Bedke, et al.. (2017). Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia. 31(10). 2181–2190. 195 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Evelyn Degenhard Breakdown of academic impact, for papers by S. Schuster Breakdown of academic impact, for papers by Marion Subklewe Breakdown of academic impact, for papers by Jan Bögeholz Breakdown of academic impact, for papers by Veit Buecklein Breakdown of academic impact, for papers by Kirstie L.S. Cleary Breakdown of academic impact, for papers by Patrycja Wawrzyniecka Breakdown of academic impact, for papers by Horst Hummel Breakdown of academic impact, for papers by Daniel Egan Breakdown of academic impact, for papers by Anna Truppel-Hartmann
Rankless by CCL
2026